

**POLYMER FREE DRUG-ELUTING STENTS VERSUS
DURABLE POLYMER DRUG-ELUTING STENTS IN
ELECTIVE PERCUTANEOUS CORONARY
INTERVENTIONS IN PATIENTS WITH STABLE
CORONARY ARTERY DISEASE PATIENTS: A SINGLE
CENTER PROSPECTIVE COMPARATIVE STUDY**

*Thesis Submitted for Partial Fulfilment of the MD
Degree in Cardiology*

Presented by

Sherif Mohammad Aziz Abdalazeem Altoukhy
M.Sc. Cardiology, Ain Shams University

Under supervision of

Prof. Mohammad Awad Ahmed Taher
Professor of Cardiology, Ain Shams University

Prof. Mohsen Fahmy Metwally Aly
Professor of Cardiology, Ain Shams University

Prof. Walid Abdelazim Mohammad Elhammady
Professor of Cardiology, Ain Shams University

Dr. Basem Alsaid Mohammad Enany
Assistant Professor of Cardiology, Ain Shams University

Dr. Ahmed Abdul Moneim Abdul Salam Rezaq
Lecturer of Cardiology, Ain Shams University

Ain Shams University
Cairo, 2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I would like to express my respectful thanks and gratitude to **Prof. Mohammad Awad Ahmed Taher**, Professor of Cardiology - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made the completion of this work possible.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Mohsen Fahmy Metwally Aly**, Professor of Cardiology, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Prof. Walid Abdelazim Mohammad Elhamady**, Professor of Cardiology, Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Basem Alsaid Enany**, Assistant Professor of Cardiology, Faculty of Medicine, Ain Shams University, for his continuous support in this work.*

*I would like to express my hearty thanks to **Dr. Ahmed Abdul Moneim Abdul Salam Rezaq**, Lecturer of Cardiology, Faculty of Medicine, Ain Shams University, for his support, kindness, supervision and cooperation in this work.*

*Sherif Mohammad Aziz
Abdalazeem Altoukhy*

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iv
Introduction	1
Aim of the Work.....	4
Review of Literature	
▪ Evolution of Coronary Stents	5
▪ Polymer free Drug-Eluting Stents	25
▪ C-Reactive Protein	40
Patients and Methods	52
Results	62
Discussion	82
Conclusion.....	95
Recommendations	97
Summary	98
References	104
Appendix	135
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Comparison of DES.....	16
Table (2):	Polymer free drug-eluting stent platforms used in clinical studies	33
Table (3):	Baseline patient characteristics	65
Table (4):	Stented vessel distribution in the patients	68
Table (5):	Stent parameters and ejection fraction distribution of the patients	70
Table (6):	Incidence of recurrence of anginal symptoms, MI and TLR	72
Table (7):	Difference between baseline and day 1 hsCRP serum level.....	74
Table (8):	Difference between the percentages of hsCRP rise in both groups.	76
Table (9):	Correlation between the percentage of hsCRP rise and the baseline patient characteristics	77
Table (10):	Correlation between the percentage of hsCRP rise and the type of the stented vessel.....	78
Table (11):	Correlation of the percentage of hsCRP rise with the stent parameters and the EF	79
Table (12):	Correlation of the percentage of hsCRP rise with the recurrence of anginal symptoms, occurrence of MI and TLR.....	80

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathogenic mechanisms of late and very late stent thrombosis	14
Figure (2):	Fate of Bioabsorbable Vascular Scaffold from implantation to complete biodegradation in an implanted artery	20
Figure (3):	The three main components of a DES, together with the potential modifications that can be carried out to improve safety and efficacy	23
Figure (4):	Biolimus-A9 polymer free coated stent (BioFreedom)	29
Figure (5):	Schematic representation of the techniques used to manufacture polymer free DES	30
Figure (6):	Kinetic profiles of polymer free DES, showing the cumulative drug released over time and the tissue concentration	34
Figure (7):	Cross-section of a stent implanted blood vessel	36
Figure (8):	C-reactive protein, pentraxin-related	41
Figure (9):	Representation of CRP-mediated effects on atherosclerosis and CHD	45
Figure (10):	Gender distribution of the patients	66
Figure (11):	Age distribution of the patients	66

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (12):	Incidence of risk factors of the patients	67
Figure (13):	Stented vessel distribution of the patients.....	68
Figure (14):	Percentage of patients with preserved vs. reduced EF.....	70
Figure (15):	Percentage of patients with recurrence of anginal symptoms and TLR.....	72
Figure (16):	Day 0 and day 1 hsCRP in patients with deployed permanent polymer DES.....	74
Figure (17):	Day 0 and day 1 hsCRP in patients with deployed polymer free DES.....	75

List of Abbreviations

Abbreviation	Full term
ACC	<i>American College of Cardiology</i>
ACS	<i>Acute coronary syndrome</i>
ADP	<i>Adenosine diphosphate</i>
AES	<i>Amphilimus-eluting stent</i>
AHA	<i>American Heart Association</i>
ARC	<i>Academic Research Consortium</i>
BA9 -DCS	<i>Biolimus -A9 polymer free coated stent</i>
BMS	<i>Bare-metal stent</i>
BP	<i>Biodegradable polymer</i>
BVS	<i>Bioabsorbable vascular scaffold</i>
CABG	<i>Coronary artery bypass grafting</i>
CD4	<i>Cluster of differentiation 4</i>
CE	<i>Conformité Européene (European conformity)</i>
CI	<i>Cardiac index</i>
CI	<i>Confidence interval</i>
CRP	<i>C-reactive protein</i>
DAPT	<i>Dual antiplatelet therapy</i>
DEB	<i>Drug-eluting balloon</i>
DES	<i>Drug-eluting stent</i>
DM	<i>Diabetes mellitus</i>
DS	<i>Diameter stenosis</i>
EACTS	<i>European Association for Cardiothoracic Surgery</i>
ECS	<i>Endothelial progenitor cell capture stent</i>
EES	<i>Everolimus eluting stent</i>
EF	<i>Ejection fraction</i>
ELISA	<i>Enzyme-linked immunosorbent assay</i>
EPC	<i>Endothelial progenitor cells</i>
ESC	<i>European Society of Cardiology</i>
FDA	<i>Food and Drug Administration</i>

List of Abbreviations (cont...)

Abbreviation	Full term
HDL	<i>High density lipoprotein</i>
HsCRP	<i>High sensitivity C-reactive protein</i>
HTN	<i>Hypertension</i>
IL-6	<i>Interleukin-6</i>
IL-12	<i>Interleukin-12</i>
IQR	<i>Interquartile range</i>
ISA	<i>Incomplete stent apposition</i>
ISR	<i>In stent restenosis</i>
IVUS	<i>Intravascular ultrasound</i>
JNC	<i>Joint national committee</i>
LAD	<i>Left anterior descending artery</i>
LCx	<i>Left circumflex artery</i>
LDL	<i>Low density lipoprotein</i>
LIMA	<i>Left internal mammary artery</i>
LLL	<i>Late lumen loss</i>
LMCA	<i>Left main coronary artery</i>
LST	<i>Late stent thrombosis</i>
LV	<i>Left ventricle</i>
MACEs	<i>Major adverse cardiac events</i>
mg	<i>Milligram</i>
MI	<i>Myocardial infarction</i>
ml	<i>Milliliter</i>
ng	<i>Nanogram</i>
NO	<i>Nitric oxide</i>
NSTACS	<i>Non-ST acute coronary syndrome</i>
NSTEMI	<i>Non-ST elevation myocardial infarction</i>
OCT	<i>Optical coherence tomography</i>
OM	<i>Obtuse marginal branch</i>
OR	<i>Odds ratio</i>

List of Abbreviations (cont...)

Abbreviation	Full term
PAI-1	<i>Plasminogen-activator inhibitor 1</i>
PCI	<i>Percutaneous coronary intervention</i>
PCWP	<i>Pulmonary capillary wedge pressure</i>
PDLLA	<i>poly-D,L-lactide</i>
PES	<i>Paclitaxel-eluting stents</i>
PF-DES	<i>Polymer free drug-eluting stent</i>
PF-PES	<i>Polymer free paclitaxel-eluting stent</i>
PF-SES	<i>Polymer free sirolimus-eluting stent</i>
PLLA	<i>Poly-L-lactic acid</i>
POBA	<i>Percutaneous old balloon angioplasty</i>
PP	<i>Permanent polymer</i>
PTCA	<i>Percutaneous transluminal coronary angioplasty</i>
RCA	<i>Right coronary artery</i>
RCTs	<i>Randomized controlled trials</i>
RES	<i>Rapamycin-eluting stent</i>
RR	<i>Risk ratio</i>
SAM	<i>Self-assembled monolayer</i>
SCAD	<i>Stable coronary artery disease</i>
SD	<i>Standard deviation</i>
SES	<i>Sirolimus eluting stent</i>
SMC	<i>Smooth muscle cells</i>
ST	<i>Stent thrombosis</i>
STEMI	<i>ST elevation myocardial infarction</i>
SVG	<i>Saphenous venous graft</i>
SWMA	<i>Segmental wall motion abnormalities</i>
TLF	<i>Target lesion failure</i>
TLR	<i>Target lesion revascularization</i>
TOR	<i>Target of Rapamycin</i>
TVR	<i>Target vessel revascularization</i>
UA	<i>Unstable angina</i>
VLST	<i>Very late stent thrombosis</i>
vs.	<i>versus</i>
ZES	<i>Zotarolimus-eluting stent</i>

INTRODUCTION

The development of DES has been pioneered through a combination of the increased understanding of the biology of restenosis, the selection of drugs that target one or more pathways in the restenotic process, controlled-release drug delivery strategies, and the use of the stent as a delivery platform. This helped in reducing the major drawback of using bare metal stents (BMS) (*Abizid and Costa, 2010*).

Although first-generation DES Cypher and Taxus have effectively achieved their main goal, reducing restenosis across virtually all lesion and patient subsets, their safety has been limited by suboptimal polymer biocompatibility, delayed stent endothelialization leading to late and very late thrombosis, and local drug toxicity (*Iakovou et al., 2005 and McFadden et al., 2004*).

The permanent presence of these polymers has been correlated to the inflammatory responses and local toxicity in preclinical analysis (*Abizid and Costa, 2010*). Consequently, the focus of clinical research has been on the development of novel drug carrier systems including biodegradable polymers and non-polymeric stent surfaces. Additional improvements include the development of more modern platforms and the use

of novel anti-proliferative agents or reduced doses of current approved anti-proliferative drugs (*Serruys et al., 2010*).

The main issue is: Will polymer free stents reduce the incidence of very late stent thrombosis, thereby lessening the need for long term dual anti platelet therapy? In addition, if so, is there a penalty to pay in terms of target lesion and target vessel revascularization? (*Bailey et al., 2012*).

A large body of evidence suggests that inflammation plays a key role in the pathogenesis of atherosclerosis. The chronic inflammatory process can develop into an acute clinical event by the induction of plaque rupture, leading to acute coronary syndromes (*Libby et al., 2002*).

C-reactive protein (CRP) has been the most extensively studied, and subsequent works demonstrated that it was a risk marker in both acute coronary syndromes and in patients with myocardial ischemia. Moreover it takes part directly in the atherosclerotic process (*Zebrak et al., 2002 and Topol, 2003*).

It was concluded that CRP was an independent predictor of adverse cardiac events in patients with stable coronary artery disease irrespective of the presence of significant atherosclerotic lesions (*Arroyo-Espliguero et al., 2009 and Worthley et al., 2006*).

Vascular injury during percutaneous coronary intervention (PCI) is associated with a systemic inflammatory

response and a rise in CRP serum level, and the degree of inflammation has been shown to correlate with the cardiovascular risk (*Jae Rhee et al., 2008*).

Most of the clinical trials in the literature focused on comparing the clinical outcome between permanent polymer and polymer free drug eluting stents, but there is little data about the inflammatory effect of the permanent polymer versus polymer free drug eluting stents in association with the clinical outcome.

Accordingly, our study aims at comparing the inflammatory responses and the clinical outcomes after percutaneous interventions, using permanent polymer versus polymer free DES in patients with SCAD. High sensitivity CRP will be our marker to assess that inflammatory response.

AIM OF THE WORK

The aim of this study is to compare the inflammatory response of polymer free versus permanent polymer drug-eluting stents in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention, and the effect of this inflammatory response on the 6 month clinical outcomes & major adverse cardiac events.

Chapter 1

EVOLUTION OF CORONARY STENTS

In the modern era, percutaneous coronary intervention (PCI) is a globally adopted standard therapy that continues to advance based on best medical practice and evolving scientific data. It is now one of the most common medical procedures performed in the United States, with over 600,000 performed annually (*Roger et al., 2012*).

In 1929, Forssmann performed the first human cardiac catheterization on himself, using a urinary catheter to measure heart pressures (*Forssmann, 1929*). This was followed by Cournand and Richards who evolved right heart catheterization to a standard diagnostic tool (*Cournand and Ranges, 1949*). For their pioneering work, and so diagnostic catheterization became an established tool for invasive hemodynamic assessment.

In 1953, Seldinger developed a safe percutaneous catheterization technique (*Seldinger, 1953*), and in 1958, the first selective coronary angiogram was performed by Sones, giving rise to the concept of diagnostic coronary angiography (*Sones, 1958*).

In 1964, the first peripheral angioplasty case was performed by Dotter who, working with Judkins, used multiple catheters of increasing diameter to expand the lumen of an